Cefaclor

FDA

• Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Staphylococci, and Streptococcus pyogenes
• Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus (author’s comment: not a first-line agent)
  • Not listed for pneumonia by ATS/IDSA 2019 guideline.
  • AECB: FDA-labeled only for cefaclor ER; dose 500 mg PO q12h x 7d
• Pharyngitis and tonsillitis caused by Streptococcus pyogenes (PCN is the drug of choice).
  • Cefaclor is not a usual preferred alternative; CDC lists cephalexin or cefadroxil among oral cephalosporin options for non-immediate penicillin allergy.
• Pyelonephritis and cystitis caused by Escherichia coli, Proteus mirabilis, Klebsiella spp, and coagulase-negative staphylococci (author’s comment: not a first-line agent)
• Skin and skin structure infections caused by Staphylococcus aureus (MSSA) and Streptococcus pyogenes